Category: Immune Research | Reading time: 5 min | For research use only
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from thymosin fraction 5 — a calf thymus extract — by Allan Goldstein and colleagues at George Washington University in 1977. It is one of the most extensively studied immunomodulatory peptides in the scientific literature, with over 200 peer-reviewed publications since 2021 alone, a figure that reflects renewed research interest following the COVID-19 pandemic and its acceleration of immunology research globally.
Unlike many research peptides that remain confined to preclinical models, Thymosin Alpha-1 has a substantial clinical trial record spanning four decades, with approved clinical applications in multiple countries and an established pharmacological profile. This makes it one of the best-characterized immunomodulatory peptides available for research use.
This article summarizes published research on Thymosin Alpha-1 for scientific and educational purposes. All compounds discussed are strictly for laboratory and research use only.
Molecular Profile
- Full name: Thymosin Alpha-1 (Tα1)
- Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
- Amino acids: 28
- Molecular weight: 3,108 g/mol
- N-terminal modification: Acetylated (Ac-Ser) — critical for biological activity
- CAS Number: 62304-98-7
- Form: Lyophilized powder (research grade); commercially available as Thymalfasin (brand name Zadaxin)
- Stability: Store at −20°C; stable lyophilized form
- Half-life: ~2 hours in plasma
The N-terminal acetylation is not a synthesis artifact — it is a required structural feature for full biological activity. Research using non-acetylated Tα1 shows reduced potency, and researchers should verify acetylation status in COA documentation.
Background and Clinical Context
Thymosin Alpha-1 has a regulatory approval history that distinguishes it from most research peptides:
- Approved in Italy (1983) and subsequently in over 35 countries for treatment of hepatitis B, hepatitis C, and as an immunomodulator in cancer patients receiving chemotherapy
- Marketed as Thymalfasin (Zadaxin) by SciClone Pharmaceuticals
- Extensive use in China for hepatitis treatment and as adjuvant therapy
- FDA orphan drug designation for DiGeorge anomaly (thymic aplasia)
- Investigated in multiple Phase 2 and Phase 3 clinical trials across infectious disease, oncology, and vaccine adjuvant applications
This clinical history provides a pharmacokinetic and safety profile that is substantially more characterized than most research peptides, making Tα1 a valuable model compound for immunomodulation research.
Mechanisms Studied in Research
Thymic T-cell maturation Thymosin Alpha-1's primary characterized mechanism involves its role in T-lymphocyte differentiation and maturation. As a thymic peptide, it acts on immature thymocytes, promoting their differentiation into functional T-cell subsets. Research has documented Tα1's interaction with T-cell receptor expression, CD marker upregulation, and the thymic microenvironment factors that govern T-cell output.
Toll-like receptor signaling Research has identified Tα1 as a ligand for Toll-like receptors 2 and 9 (TLR2 and TLR9) — pattern recognition receptors of the innate immune system that detect microbial signatures and initiate immune activation cascades. This TLR interaction provides a mechanistic basis for Tα1's documented effects on dendritic cell activation, natural killer (NK) cell activity, and cytokine production in preclinical models.
Dendritic cell and NK cell activation Multiple studies have examined Tα1's effect on dendritic cell maturation and antigen presentation capacity. Research has reported upregulation of co-stimulatory molecules (CD80, CD86) and MHC class II expression on dendritic cells treated with Tα1, with downstream enhancement of T-cell priming efficiency documented in co-culture models.
Cytokine regulation Published research documents Tα1's association with modulation of cytokine profiles in treated subjects and cell models. Studies have reported increased production of Th1-associated cytokines (IFN-γ, IL-2, IL-12) and in some models suppression of excessive Th2 or inflammatory cytokine responses, suggesting a regulatory rather than uniformly stimulatory immunological profile.
Antiviral research A substantial body of research has examined Tα1 in viral infection models, motivated by its approved clinical use in hepatitis. Studies have investigated interferon pathway activation, viral replication inhibition in cell culture models, and immune parameter changes in antiviral research contexts. Post-COVID research has expanded this to SARS-CoV-2 models examining whether Tα1 modulates the immune dysregulation associated with severe COVID-19.
Autophagy induction More recent research has examined Tα1's role in autophagy — the cellular self-cleaning process by which damaged proteins and organelles are degraded and recycled. Studies have documented Tα1-associated upregulation of autophagy markers in macrophage and dendritic cell models, with researchers proposing this mechanism may contribute to its antiviral and anti-tumor activity by enhancing intracellular pathogen clearance.
Areas of Active Research
Post-COVID immune dysregulation The COVID-19 pandemic significantly accelerated Thymosin Alpha-1 research. Studies examining Tα1 in COVID-19 contexts investigated its potential to modulate the cytokine storm associated with severe disease, support T-cell recovery in lymphopenic patients, and serve as an immune adjuvant in vaccination strategies. Clinical trials conducted in Italy and China during 2020–2022 generated published data on Tα1 use in hospitalized COVID-19 patients.
Oncology — immune checkpoint and adjuvant models Research examining Tα1 in cancer immunology contexts has investigated its use alongside checkpoint inhibitor therapy (anti-PD-1, anti-CTLA-4), as an adjuvant to tumor antigen vaccines, and in models of chemotherapy-induced immunosuppression recovery. The compound's T-cell and NK cell activation profile makes it mechanistically complementary to immune checkpoint strategies.
Vaccine adjuvant research Studies have examined Tα1 as an immune adjuvant — a compound that enhances the immune response to co-administered antigens. Research in animal models has documented enhanced antibody titers and T-cell responses when Tα1 is administered alongside experimental vaccines.
Sepsis and critical illness models Tα1 has been investigated in sepsis models examining immune paralysis — the state of profound immune suppression that frequently follows initial hyperinflammation in critically ill patients. Research in animal sepsis models and small clinical studies has examined whether Tα1 can restore impaired lymphocyte function in this context.
Aging and immunosenescence The decline in thymic function with age (thymic involution) reduces T-cell output and contributes to immunosenescence — the age-related deterioration in immune function. Research in aged animal models has examined whether Tα1 supplementation can partially compensate for reduced thymic output and restore T-cell diversity parameters.
Key Published Research
- Goldstein AL, et al. (1977). Thymosin alpha one: isolation and sequence analysis of an immunologically active thymic polypeptide. Proceedings of the National Academy of Sciences, 74(2), 725–729.
- Dominari A, et al. (2021). Thymosin alpha 1: A comprehensive review of the literature. World Journal of Virology, 10(3), 101–120.
- Liu Y, et al. (2020). Thymosin Alpha-1 (Tα1) Reduces the Mortality of Severe COVID-19 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clinical Infectious Diseases, 71(16), 2150–2157.
- Garg AD, et al. (2019). Trial watch: Thymosin-α1 for the treatment of cancer. OncoImmunology, 8(12), e1670049.
- Romani L, et al. (2004). Thymosin α1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood, 108(7), 2265–2274.
Research Considerations
Thymosin Alpha-1's immunomodulatory profile is context-dependent — its effects on cytokine production and immune cell activation vary depending on baseline immune status, disease context, and co-administered compounds. Researchers should interpret findings from specific disease models carefully before extrapolating to other contexts.
The peptide's well-characterized clinical safety profile across decades of approved use provides a useful foundation for research design, but differences between therapeutic and research-grade preparations (purity, formulation, batch consistency) should be verified through COA documentation before experimental use.
The N-terminal acetylation is essential — confirm this modification is present in your research compound.
NordBioLab supplies Thymosin Alpha-1 as a research-grade lyophilized peptide with ≥98% purity (HPLC verified), confirmed N-terminal acetylation, and full COA documentation per batch.
View Thymosin Alpha-1 in our catalog →
All products and information provided by NordBioLab are strictly for scientific research and laboratory use only. Not for human or veterinary consumption. This article does not constitute medical advice.